Mifepristone (RU-486) treatment for depression and psychosis: a review of the therapeutic implications
Open accessThe DOI matches its OpenAlex record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
The mechanisms underlying the pathophysiology of severe psychiatric illnesses are complex, involving multiple neuronal and neurochemical pathways. A growing body of evidence indicates that alterations in hypothalamic-pituitary-adrenal (HPA) axis function may be a trait marker in both mood disorders and psychosis, and may exert significant causal and exacerbating effects on symptoms and neurocognition. At present, however, no available treatments preferentially target HPA axis abnormalities, although many drugs do increase feedback-regulation of the HPA axis at the level of the glucocorticoid receptor (GR). This action may in part underpin their therapeutic efficacy. Therapeutic interventions directly targeted at GR function may therefore have clinical benefit. The present review examines the current literature for the clinical utility of GR antagonists (specifically mifepristone) in mood disorders and psychosis. At present, most studies are at the "proof-of-concept" stage, although the results of preliminary, randomized, controlled trials are encouraging. The optimum strategy for the clinical application of GR antagonists is yet to be established, their potential role as first-line or adjunctive treatments being unclear. The therapeutic utility of such drugs will become known within the next few years following the results of larger clinical trials currently underway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The acute effects of corticosteroids on cognition: integration of animal and human model studies
LUPIEN, S., & MCEWEN, B. (1997) · Brain Research Reviews · doi:10.1016/s0165-0173(97)00004-0 · Cited by 1,024 · cited 2×
“This may be particularly so for neurocognitive functioning, which depends on the relative ratio of corticosteroid receptor occupancy (Lupien and McEwen 1997).”
Cognitive Impairment in Schizophrenia Is the Core of the Disorder
Elvevag, B., & Goldberg, T. E. (2000) · Critical Reviews™ in Neurobiology · doi:10.1615/critrevneurobiol.v14.i1.10 · Cited by 835 · cited 1×
“In schizophrenia, the symptomatic clinical profile of the illness is complex and diverse, but neurocognitive impairment is consistently reported and some authors have argued that such impairments may be the cardinal feature of the illness (Elvevag and Goldberg 2000).”
Zobel, A. W., Nickel, T., Künzel, H. E., Ackl, N., Sonntag, A., Ising, M., & Holsboer, F. (2000) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(00)00016-9 · Cited by 705
Neurocognitive impairment in drug-free patients with major depressive disorder
Porter, R. J., Gallagher, P., Thompson, J. M., & Young, A. H. (2003) · British Journal of Psychiatry · doi:10.1192/bjp.182.3.214 · Cited by 519
Self-citationWebster, M. J., Knable, M. B., O'Grady, J., Orthmann, J., & Weickert, C. S. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001139 · Cited by 420 · cited 3×
“Studies have found evidence of reduced glucocorticoid receptor ( GR) mRNA expression in post-mortem brain tissue samples from patients with mood disorders and psychosis (Knable et al 2001; Webster et al 2002; Lopez et al 2003).”
Deuschle, M., Schweiger, U., Weber, B., Gotthardt, U., Körner, A., Schmider, J., Standhardt, H., Lammers, C.-H., & Heuser, I. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.1.3689 · Cited by 344
An open label trial of C-1073 (mifepristone) for psychotic major depression*
Belanoff, J. K., Rothschild, A. J., Cassidy, F., DeBattista, C., Baulieu, E.-E., Schold, C., & Schatzberg, A. F. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01432-4 · Cited by 320
Young, A. H., Gallagher, P., Watson, S., Del-Estal, D., Owen, B. M., & Nicol Ferrier, I. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300471 · Cited by 318 · cited 3×
“Utilizing the same experimental design as described above (Young et al 2004), we have recently completed the first trial to examine the efficacy of adjunctive mifepristone administration in schizophrenia (Gallagher et al 2005).”
Self-citationRapid Reversal of Psychotic Depression Using Mifepristone
Belanoff, J. K., Flores, B. H., Kalezhan, M., Sund, B., & Schatzberg, A. F. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200110000-00009 · Cited by 282
Dorn, L. D., Burgess, E. S., Friedman, T. C., Dubbert, B., Gold, P. W., & Chrousos, G. P. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.3.3834 · Cited by 260 · cited 1×
“…and in conditions associated with a chronic elevation of endogenous cortisol levels, for example Cushing’s disease (Starkman et al 2001; Forget et al 2002), which is also associated with a high incidence of depression that notably resolves with correction of the hypercortisolemia (Dorn et al 1997).”
Glucocorticoid and mineralocorticoid receptor mRNA expression in squirrel monkey brain
Patel, P. D., Lopez, J. F., Lyons, D. M., Burke, S., Wallace, M., & Schatzberg, A. F. (2000) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(00)00035-2 · Cited by 252 · cited 1×
“The MR is highly expressed in the limbic system whereas the GR is ubiquitous, being present in both subcortical and cortical structures, with a preferential distribution in the prefrontal cortex (Patel et al 2000).”
Ryan, M. C. M., Sharifi, N., Condren, R., & Thakore, J. H. (2004) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2003.08.011 · Cited by 225 · cited 1×
“Hypercortisolism has also been recognized in symptomatic schizophrenic patients (Ritsner et al 2004; Ryan et al 2004).”
Mineralocorticoid Receptor Function in Major Depression
Young, E. A., Lopez, J. F., Murphy-Weinberg, V., Watson, S. J., & Akil, H. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.24 · Cited by 204 · cited 1×
“There is some evidence, however, that MR function may be normal or even enhanced in mood disorders (Young et al 2003).”
Corticosteroid Receptor Function Is Decreased in Depressed Patients
Modell, S., Yassouridis, A., Huber, J., & Holsboer, F. (2008) · Neuroendocrinology · doi:10.1159/000127275 · Cited by 204
Metyrapone as Additive Treatment in Major Depression: A Double-blind and Placebo-Controlled Trial
Jahn, H., Schick, M., Kiefer, F., Kellner, M., Yassouridis, A., & Wiedemann, K. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.12.1235 · Cited by 184
Corticosteroid–serotonin interactions in depression: a review of the human evidence
Porter, R. J., Gallagher, P., Watson, S., & Young, A. H. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1774-1 · Cited by 169 · cited 1×
“HPA axis dysregulation therefore has been suggested to be one of the principal causes of both low mood and neurocognitive impairment, possibly through interactions with other neurotransmitter system (McAllister-Williams et al 1998; Porter et al 2004).”
Self-citationGlucocorticoid Receptor Function In Vitro in Patients with Major Depression
Pariante, C. M. (2004) · Stress · doi:10.1080/10253890500069650 · Cited by 147
LAUE, L., LOTZE, M. T., CHROUSOS, G. P., BARNES, K., LORIAUX, D. L., & FLEISHER, T. A. (1990) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-71-6-1474 · Cited by 77 · cited 2×
“Laue and colleagues reported that in healthy male normal volunteers who received mifepristone (10 mg/kg/day), 8 of 11 subjects developed generalized exanthem after 9 days.”
Simpson, G. M., Sheshai, A. E., Loza, N., Kingsbury, S. J., Fayek, M., Rady, A., & Fawzy, W. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0509 · Cited by 63
Cited by
Biomarkers for depression: recent insights, current challenges and future prospects
Strawbridge, R., Young, A. H., & Cleare, A. J. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s114542 · Cited by 415
Self-citationAiello, G., Horowitz, M., Hepgul, N., Pariante, C. M., & Mondelli, V. (2012) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2012.05.003 · Cited by 141
Simms, J. A., Haass-Koffler, C. L., Bito-Onon, J., Li, R., & Bartlett, S. E. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.268 · Cited by 97
Metadata
- Authors
- Gallagher, P., & Young, A. H.
- Venue
- Neuropsychiatric Disease and Treatment
- Publisher
- Dove Medical Press
- Published
- 2006-03-01
- Volume
- Volume 2
- Issue
- 1
- Pages
- 33-42
- ISSN
- 1176-6328 (ISSN-L)
- OpenAlex
- W74340424
- Cited by
- 47
- References
- 19
- FWCI
- 0.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.